

## Macular Degeneration Guideline Committee – development

**Date:** 24<sup>th</sup> and 25<sup>th</sup> May 2016

**Location:** NICE offices, London

**Minutes:** Final

### Committee members present:

	Day 1	Day 2
Waqaar Shah (Chair)	Present for all items	Present for all items
Katy Barnard (KB)	Present for all items	Present for all items
Nick Beare (NB)	Present for all items	Present for all items
Cathie Burke (CB)	Present for all items	Present for all items
Mary Freeman (MF)	Present for all items	Present for all items
Alexander Foss (AF)	Present for all items	Present for all items
Carol McCletchie (CM)	Present for all items	Present for all items
Ellen Rule (ER)	Present from item 3	Present for all items
Mary-Ann Sherratt (MAS)	Present for all items	Present for all items
Elizabeth Wick (EW)	Present until part way through item 4	Present for all items
Cathy Yelf (CY)	Present from item 2	Present for all items

### In attendance:

	Day 1	Day 2
Louisa Crossley (LC) NICE – Senior Medicines Advisor	Present from item 2 to part way through	Apologies

## Macular Degeneration Guideline Committee 7 minutes

	item 4	
Sue Ellerby (SE) ICG – Clinical Advisor	Present for all items	Present until part way through item 3
Chris Gibbons (CG) ICG – Technical Analyst (HE)	Present for all items	Present for all items
Vonda Murray (VM) ICG – Project Manager	Present for all items	Present for all items
Gabriel Rogers (GR) ICG – Technical Advisor (HE)	Present for all items	Present for all items
Yingying Wang (YW) ICG – Technical Analyst	Present for all items	Present for all items

### Observers:

Judith Hughes	PhD student
---------------	-------------

### Apologies:

Andy Charley	Committee member
Jennifer Evans	Committee member
Caroline Keir	NICE – Guideline Commissioning Manager
Dave Nicholls	NICE – Information Specialist
Sue Spiers	NICE – ICG, Associate Director

## DAY 1

### 1. Introductions, apologies, minutes, DOI and objectives for the meeting

The Chair welcomed the Committee members, attendees and observers to day 1 of the 7th meeting on age-related macular degeneration (AMD). The committee members, attendees and observers introduced themselves. The Chair welcomes Nick Beare, new member to the committee.

Apologies were noted, as recorded above.

The Chair invited each attendee to declare any new conflicts since the previous meeting. The following conflicts were noted;

Attendee	Declaration	Action
Nick Beare	Advise AbbVie for approximately a year (from May 2016), on the identification of uveitis research questions. The company do not make any AMD related products	Declare and participate

Having reviewed all previous and new declarations of interest it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The minutes were reviewed from GComm 6; 06/04/2016. Two corrections where noted;

- Remove Mary Freeman's name from the apologies
- Correct the spelling of LEVO to LEAVO

Subject to the amendments noted above the minutes were agreed to be an accurate record.

### VM to update the minutes

The Chair provided a brief overview of the objectives for the day highlighting the information that would be discussed.

**2. RQ13 What is the effectiveness of adjunctive therapies for the treatment of neovascular AMD?**

YW presented the evidence regarding the effectiveness of adjunctive therapies for the treatment of neovascular AMD. CG presented the health economics data found for adjunctive therapies and AMD.

The committee discussed the evidence. Recommendations were made including research recommendations.

**3. Review one page summary**

The committee reviewed the classification scheme, alterations were agreed.

**4. Feedback discussion;**

**RQ 19 How often should people with early AMD, intermediate AMD, or advance geographic atrophy be reviewed?**

**RQ 20 How often should people with early AMD, intermediate AMD, or advance geographic atrophy have their non-affected eye reviewed?**

**RQ 21 In people with neovascular AMD for whom treatment has been deferred how often should they be reviewed?**

**RQ 22 How often should people with neovascular AMD have their non-affected eye reviewed?**

The committee discussed the recommendations made at the last committee meeting. Alterations were agreed by the committee, and the AMD classification was updated to reflect discussions.

**5. AOB**

None

**6. Summary and next steps**

The Chair briefly summarised the discussions from the meeting before closing day 1.

## DAY 2

### **1. Introductions, apologies, minutes, DOI and objectives for the meeting**

The Chair welcomed the Committee members, attendees and observers to day 2 of the 7th meeting on age-related macular degeneration (AMD).

Apologies were noted, as recorded above.

The Chair invited each attendee to declare any new conflicts, no conflicts were declared.

Having reviewed all declarations of interest it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations. The Chair provided a brief overview of the objectives for the day highlighting the information that would be discussed.

### **2. RQ4 What tools are useful for triage, diagnosis, informing treatment and determining management in people with suspected AMD?**

YW presented the evidence regarding what tools are useful for triage, diagnosis, informing treatment and determining management in people with suspected AMD. CG presented the health economics found. The committee discussed the evidence, and recommendations were made including research recommendations.

### **3. RQ 17 What are the barriers to appointment attendance and uptake of treatment for people with AMD?**

YW summarised the agreed protocol, and provided an overview of CERQual which has been used to assess qualitative data. YW went onto present the evidence found on what the barriers to appointment attendance and uptake of treatment for people with AMD. The evidence was discussed by the committee and recommendations were made.

### **4. AOB**

None

### **6. Summary and next steps**

The Chair thanked the committee for their time and contribution to the

**Macular Degeneration Guideline Committee 7 minutes**

meeting. The venue, date and time of the next meeting was confirmed.

<b>Date of next meeting:</b>	GDG 8 - Wednesday 13 <sup>th</sup> July 2016
<b>Location of next meeting:</b>	NICE offices, Manchester